Home > News > Clinical trials put dendrimers on course for treating HIV
September 24th, 2003
Clinical trials put dendrimers on course for treating HIV
Abstract:
They might be nano’s artificial molecule, but dendrimers are taking real steps toward fighting HIV and sexually transmitted diseases in women. Starpharma Pooled Development Ltd. of Melbourne, Australia, gained approval in July from the U.S. Food and Drug Administration to start human trials of VivaGel, a dendrimer-based topical gel designed to prevent or reduce disease transmission during sexual intercourse. It’s the first dendrimer – and defined nanostructure – cleared for clinical testing, according to John Raff, Starpharma’s chief executive.
Source:
SmallTimes
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||